Arcus BiosciencesRCUS +0.26%46 PS Ratio is 14.39 as of Jun. 30, 2026, which is 18% above its 10-year median of 12.17. GuruFocus rates RCUS with a GF Score™ of 46/100 and a GF Value™ of $13.76 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 935 Biotechnology companies, Arcus Biosciences ranks worse than 60.21% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Arcus Biosciences's share price is $31.08.
Arcus Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.16. Hence, Arcus Biosciences's PS Ratio for today is 14.39.
Warning Sign:
Arcus Biosciences Inc stock PS Ratio (=14.35) is close to 3-year high of 14.35.
The historical rank and industry rank for Arcus Biosciences's PS Ratio or its related term are showing as below:
RCUS'
s PS Ratio Range Over the Past 10 Years
Min: 2.8 Med: 12.17 Max: 488.89
Current: 14.41
During the past 10 years, Arcus Biosciences's highest PS Ratio was 488.89. The lowest was 2.80. And the median was 12.17.
RCUS's PS Ratio is ranked worse than 60.21% of 935
companies
in the Biotechnology industry
Industry Median: 9.29
vs RCUS: 14.41
During the past 12 months, the average Revenue per Share Growth Rate of Arcus Biosciences was 41.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 13.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 1.90% per year.
During the past 10 years, Arcus Biosciences's highest 3-Year average Revenue per Share Growth Rate was 250.70% per year. The lowest was -17.90% per year. And the median was 39.80% per year.
Back to Basics: PS Ratio
Arcus Biosciences (NYSE:RCUS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Arcus Biosciences PS Ratio Related Terms
Arcus Biosciences PS Ratio Historical Data
* Premium members only.
The historical data trend for Arcus Biosciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arcus Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Arcus Biosciences's Share Price of today is $31.08. Arcus Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Arcus Biosciences (RCUS) has a PS Ratio of 14.39 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Arcus Biosciences and its competitors. This is 18% above median its historical median of 12.17. Over the past decade, Arcus Biosciences' PS Ratio has ranged from 2.80 to 488.89. According to the industry distribution chart, Arcus Biosciences ranks #563 out of 935 companies in the Biotechnology industry, placing it in the top 60.2%.
Is Arcus Biosciences' PS Ratio too high?
Arcus Biosciences' current PS Ratio of 14.39 is 18% above median its 10-year median of 12.17. Over the past 10 years, this metric has ranged from a low of 2.80 to a high of 488.89. The Biotechnology industry median PS Ratio is 9.29. Arcus Biosciences' value of 14.39 is 54.9% above this industry median. Based on the distribution chart, Arcus Biosciences ranks #563 out of 935 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Arcus Biosciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' PS Ratio compare to NAMS and CRNX?
According to the Biotechnology industry distribution chart, Arcus Biosciences ranks #563 out of 935 companies for PS Ratio. This places Arcus Biosciences in the lower half of its industry. The industry median PS Ratio is 9.29. Arcus Biosciences' value of 14.39 is 54.9% above this benchmark. Historically, Arcus Biosciences' own PS Ratio has ranged from 2.80 to 488.89 over the past decade. While the company's 10-year median is 12.17 vs. the industry median of 9.29, Arcus Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.29, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcus Biosciences's current PS Ratio of 14.39 is 54.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Arcus Biosciences and its competitors. For the Biotechnology industry, the median PS Ratio is 9.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcus Biosciences's current PS Ratio is 14.39, which is 18% above median its own 10-year median of 12.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.76, compared to a current price of $31.08 — trading 125.9% above its estimated fair value. The current PS Ratio is 14.39, which is 18% above median its 10-year median of 12.17 and 54.9% above the Biotechnology industry median of 9.29. Arcus Biosciences' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current PS Ratio is 14.39 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcus Biosciences (RCUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued.
The current stock price of $31.08 is trading 125.9% above its estimated GF Value™ of $13.76.
GuruFocus considers Arcus Biosciences to be Significantly Overvalued.
Key valuation signals for RCUS:
PS Ratio: 14.39 (18% above median its 10-year median of 12.17)
GF Value™: $13.76 vs. price of $31.08 (125.9% above fair value)
Industry Position: 54.9% above the Biotechnology median (#563 of 935)
No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score
Get the complete analysis for RCUS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RCUS has been successfully added to your 
